** Shares of Australia's Amplia Therapeutics ATX.AX rise
as much as 7.4% to A$0.145, on track to record their second
consecutive day of gains, if trend holds
** The drug developer says it has been granted a key patent
in Europe and Japan
** Patent for a chemical form of co's FAK inhibitor
Narmafotinib
** Narmafotinib is the inhibitor of the protein FAK, a
protein overexpressed in pancreatic and other cancers, drug
target gaining increasing attention for its role in solid
tumours - ATX
** Nearly 1.1 mln shares change hands, vs 30-day average
volume of 765,686 shares
** Stock up 73.6% YTD, as of last close
(Reporting by Roshan Thomas in Bengaluru)
((Roshan.Thomas@thomsonreuters.com))